Results 131 to 140 of about 39,319 (333)
Ibrutinib-Associated Atrial Fibrillation
Ibrutinib, a novel and potent Bruton tyrosine kinase inhibitor, is an effective and well-tolerated treatment for a variety of B-cell lymphomas. However, its use is associated with an increased incidence of atrial fibrillation (AF), ranging from 4% to 16%. We reviewed the original clinical trials that led to the approval of ibrutinib, as well as several
David M. Venesy+13 more
openaire +3 more sources
MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells. [PDF]
Prostate cancer is the most commonly diagnosed cancer in men with African American men disproportionally suffering from the burden of this disease.
Aqeel, Rasha+10 more
core +1 more source
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner+7 more
wiley +1 more source
Patient‐derived xenograft models in pan‐cancer: From bench to clinic
Abstract Patient‐derived xenograft (PDX) models provide a robust preclinical platform that preserves the genetic and phenotypic heterogeneity of patient tumors while mirroring their tumor genetic characteristics, which retain malignant cells and the tumor pathological structure, making them valuable for studying tumor progression and developing ...
Jiatong Li+5 more
wiley +1 more source
Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy.
Anthony R. Mato+25 more
doaj +1 more source
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib [PDF]
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy.
FIORCARI, STEFANIA+5 more
core +1 more source
Abstract Graft versus host disease (GVHD) is a complication that frequently occurs after haematopoietic stem cell transplantation and concerns many children in paediatric haematology‐oncology and bone marrow transplantation departments. It can affect various organs, with the skin, gastrointestinal tract and liver being the most commonly involved.
Marina Vincent+12 more
wiley +1 more source
Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells [PDF]
Background: Roughly 80% of patients with acute myeloid leukaemia have high activity of Bruton's tyrosine-kinase (BTK) in their blast cells compared with normal haemopoietic cells, rendering the cells sensitive to the oral BTK inhibitor ibrutinib in vitro.
Advani+43 more
core +1 more source
Ionic Liquid Aided [11C]CO Fixation for Synthesis of 11C‐carbonyls
Tributyl(ethyl)phosphonium oxopentenolate ([P4442][Pen]) is an ionic liquid used in a proof‐of‐concept study evaluating its utility to trap carbon‐11 (t1/2=20.4 min)‐labeled CO for preparation of amides, ureas and carbamates. Abstract Tributyl(ethyl)phosphonium oxopentenolate ([P4442][Pen]) is an ionic liquid developed to capture CO and has shown ...
Anton Lindberg+5 more
wiley +1 more source
Atrial fibrillation (AF) occurs in up to 11% of cancer patients treated with ibrutinib. The pathophysiology of ibrutinib promoted AF is complicated, as there are multiple interactions involved; the detailed molecular mechanisms underlying this are still ...
Xinyu Yang+12 more
doaj